Valuation: Madrigal Pharmaceuticals, Inc.

Market Cap 1.18TCr 1.01TCr 950.11Cr 867.87Cr 1.64TCr 1,12800Cr 1.65TCr 11TCr 4.36TCr 57TCr 4.44TCr 4.35TCr 1,88500Cr P/E 2026 *
-81.1x
P/E 2027 * 81.4x
Enterprise Value 1.13TCr 969.02Cr 907.99Cr 829.4Cr 1.57TCr 1,07800Cr 1.58TCr 11TCr 4.17TCr 54TCr 4.25TCr 4.15TCr 1,80100Cr EV / Sales 2026 *
7.41x
EV / Sales 2027 * 5.08x
Free-Float
94.12%
Yield 2026 *
-
Yield 2027 * -
1 day+0.04%
1 week-2.33%
Current month+9.60%
1 month-5.94%
3 months-0.99%
6 months+17.74%
Current year-12.05%
1 week 506.29
Extreme 506.29
539.73
1 month 447.01
Extreme 447.01
566.18
Current year 416.21
Extreme 416.21
598.79
1 year 393.6
Extreme 393.605
615
3 years 119.76
Extreme 119.7604
615
5 years 52.33
Extreme 52.33
615
10 years 9.63
Extreme 9.63
615
Manager TitleAgeSince
Chief Executive Officer 59 08/09/2023
Director of Finance/CFO 62 11/03/2024
Chief Tech/Sci/R&D Officer 58 21/04/2025
Director TitleAgeSince
Director/Board Member 74 01/07/2016
Director/Board Member 68 11/08/2016
Director/Board Member 64 27/06/2019
Date Insider Type Main position Quantity % Market Cap.
17/08/26 Sell

General Counsel

-664 0.0029%
15/08/26 Free

Director

1,725 0.0075%
20/07/26 Sell

Chief Executive Officer

-2,500 0.0108%
Change 5-day change 1-year change 3-year change Capi.($)
+0.04%-2.33%+24.24%+185.61% 1.18TCr
+3.31%-3.70%+61.03%+103.64% 7.14TCr
+1.96%+2.21%+49.85%+91.01% 6.42TCr
+1.09%+22.96%+8.55%-3.03% 2.86TCr
-0.07%-3.56%-3.45%+467.26% 2.71TCr
-2.78%+5.95%+55.58%+12.15% 2.73TCr
-0.39%+1.58%+38.57%-16.88% 2.05TCr
+1.02%+6.43%+269.42%+420.34% 1.94TCr
-0.57%-0.57%+7.19%+538.65% 1.6TCr
+3.98%+6.78%+49.66%+157.94% 1.41TCr
Average +0.77%+3.78%+56.06%+195.67% 3TCr
Weighted average by Cap. +1.26%+3.09%+54.39%+156.31%

Financials

2026 *2027 *
Net sales 152.63Cr 130.79Cr 122.55Cr 111.94Cr 211.26Cr 15TCr 213.35Cr 1.45TCr 562.74Cr 7.34TCr 573.09Cr 560.61Cr 24TCr 214.49Cr 183.8Cr 172.22Cr 157.31Cr 296.88Cr 20TCr 299.81Cr 2.03TCr 790.82Cr 10TCr 805.36Cr 787.82Cr 34TCr
Net income -18Cr -16Cr -15Cr -13Cr -25Cr -1.75TCr -26Cr -174.14Cr -68Cr -884.37Cr -69Cr -68Cr -2.93TCr 20Cr 17Cr 16Cr 15Cr 28Cr 1.91TCr 28Cr 189.42Cr 74Cr 961.95Cr 75Cr 73Cr 3.19TCr
Net Debt -52Cr -45Cr -42Cr -38Cr -73Cr -5TCr -73Cr -496.78Cr -193.39Cr -2.52TCr -196.95Cr -192.66Cr -8.35TCr -94Cr -81Cr -76Cr -69Cr -130.56Cr -8.99TCr -131.84Cr -893.33Cr -347.77Cr -4.54TCr -354.16Cr -346.44Cr -15TCr
Logo Madrigal Pharmaceuticals, Inc.
Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a liver disease with high unmet medical need. The Company’s medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-b agonist designed to target key underlying causes of MASH. Rezdiffra is the medication approved by the United States Food and Drug Administration (FDA) for the treatment of MASH with moderate to advanced fibrosis (consistent with stages F2 to F3). Rezdiffra is a prescribed medicine used along with diet and exercise to treat adults with nonalcoholic steatohepatitis (NASH) with moderate to advanced liver scarring (fibrosis), but not with cirrhosis of the liver. An ongoing Phase III outcomes trial is evaluating Rezdiffra for the treatment of compensated MASH cirrhosis (consistent with stage F4c).
Employees
915
Date Price Change Volume
25/26/25 $512.16 +0.04% 1,89,200
24/26/24 $511.97 -0.92% 1,45,523
21/26/21 $516.74 -0.45% 1,79,832
20/26/20 $519.09 -3.90% 2,64,483
19/26/19 $540.16 +3.01% 2,21,134
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
17
Last Close Price
512.16USD
Average target price
678.06USD
Spread / Average Target
+32.39%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. MDGL Stock